VigeneTech And Research Groups At NIH / National Cancer Institute And FDA Announce The Deployment Of MicroVigeneTM 2.0 For Reserve Phase Protein Microarray Analysis
10/19/2005 5:10:38 PM
MicroVigeneTM 2.0 extends VigeneTech’s flagship microarray image analysis software to support Reserve Phase Protein Microarray analysis. The new release is a result of close collaboration between VigeneTech and the inventors of the Reverse Phase Protein Microarray methodology -the teams of Dr. Lance Liotta, Chief, Laboratory of Pathology, NIH/NCI and Dr. Emanuel Petricoin, Co-Director, NCI-FDA Clinical Proteomics Program. Scientists of both research teams are now routinely using the software. MicroVigeneTM 2.0 significantly speeds up the data analysis process of the Reserve Phase Protein Microarray analysis, offers powerful tools to support various image layouts and dilution curve designs, and brings this exciting technology to a new level of implementation whereby reproducibility, precision and accuracy can be analyzed very quickly. The deployment of MicroVigeneTM 2.0 is a significant step toward high quality and reproducible standard procedure of Reverse Phase Protein Microarray analysis for the NCI-FDA clinical proteomics program and eventual clinical implementation.
comments powered by